The Phase 2 trial provides the most detailed safety data by dose level
In small studies, GLP-1RAs resulted in modest weight loss in end-stage renal disease and renal transplant recipients (113)
Many patients with commercial insurance can access GLP-1 medications for between \$150\$300 per month out-of-pocket, according to multiple clinics and real-world testimonials
While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)
Studies show that within 12-18 months of stopping semaglutide, participants regained approximately two-thirds of the weight they had lost
Journal of Trace Elements in Medicine and Biology, 81 , 127338